

World Journal of *Gastroenterology*

World J Gastroenterol 2023 December 7; 29(45): 5945-6021



EDITORIAL

- 5945 Gut microbiota in women: The secret of psychological and physical well-being
Marano G, Traversi G, Gaetani E, Gasbarrini A, Mazza M

ORIGINAL ARTICLE

Observational Study

- 5953 Enduring association between irritable bowel syndrome and war trauma during the Nicaragua civil war period: A population-based study
Peña-Galo EM, Wurzelmann D, Alcedo J, Peña R, Cortes L, Morgan D
- 5962 Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study
Lee GB, Huh Y, Lee SH, Han B, Kim YH, Kim DH, Kim SM, Choi YS, Cho KH, Nam GE

Basic Study

- 5974 Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis
Yang ZY, Zhao YW, Xue JR, Guo R, Zhao Z, Liu HD, Ren ZG, Shi M
- 5988 Pien Tze Huang alleviates Concanavalin A-induced autoimmune hepatitis by regulating intestinal microbiota and memory regulatory T cells
Zeng X, Liu MH, Xiong Y, Zheng LX, Guo KE, Zhao HM, Yin YT, Liu DY, Zhou BG

LETTER TO THE EDITOR

- 6017 Intestinal barrier in inflammatory bowel disease: A bibliometric analysis
Luan WY, Yang Z, Chen XD, Zhang TT, Zhang F, Miao YD

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Andrew S Day, MB, ChB, MD, FRACP, AGAF, Professor of Paediatrics, Department of Paediatrics, University of Otago, Christchurch 8041, New Zealand. andrew.day@otago.ac.nz

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

December 7, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Gut microbiota in women: The secret of psychological and physical well-being

Giuseppe Marano, Gianandrea Traversi, Eleonora Gaetani, Antonio Gasbarrini, Marianna Mazza

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Angelidi AM, United States; Mandal P, India

Received: October 3, 2023

Peer-review started: October 3, 2023

First decision: October 23, 2023

Revised: October 31, 2023

Accepted: November 21, 2023

Article in press: November 21, 2023

Published online: December 7, 2023



Giuseppe Marano, Marianna Mazza, Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome 00168, Italy

Giuseppe Marano, Marianna Mazza, Unit of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00168, Italy

Gianandrea Traversi, Unit of Medical Genetics, Department of Laboratory Medicine, Fatebenefratelli Isola Tiberina-Gemelli Isola, Rome 00186, Italy

Eleonora Gaetani, Department of Medical and Surgical Sciences, Università Cattolica del Sacro Cuore, Rome 00168, Italy

Eleonora Gaetani, Internal Medicine and Gastroenterology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00168, Italy

Antonio Gasbarrini, Medicina Interna e Gastroenterologia, CEMAD Digestive Disease Center, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome 00168, Italy

Corresponding author: Marianna Mazza, MD, PhD, Assistant Professor, Department of Neurosciences, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, Rome 00168, Italy. marianna.mazza@policlinicogemelli.it

Abstract

The gut microbiota works in unison with the host, promoting its health. In particular, it has been shown to exert protective, metabolic and structural functions. Recent evidence has revealed the influence of the gut microbiota on other organs such as the central nervous system, cardiovascular and the endocrine-metabolic systems and the digestive system. The study of the gut microbiota is outlining new and broader frontiers every day and holds enormous innovation potential for the medical and pharmaceutical fields. Prevention and treatment of specific women's diseases involves the need to deepen the function of the gut as a junction organ where certain positive bacteria can be very beneficial to health. The gut microbiota is unique and dynamic at the same time, subject to external factors that can change it, and is capable of modulating itself at different stages of a woman's life, playing an important role that arises from the intertwining of biological mechanisms between the microbiota and the female genital system. The gut microbiota could play a key role in personalized medicine.

Key Words: Gut microbiota; Women; Metabolites; Health promotion; Immune system; Gut-brain axis

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The function of the gut microbiota on health is of primary importance, as it educates and controls the immune system, allows to metabolize and absorb nutrients correctly and protects from pathogens invasion. This paper focuses on the importance of the microbiota for women's physical and psychological well-being. The gut microbiota has a strategic role in crucial moments at every stage of a woman's life: From childhood to adolescence, from fertile age to pregnancy-partum, up to menopause. In the future, the study of the gut microbiota could be useful in the treatment of autoimmune and metabolic diseases and even in the fight against tumors, allowing the latest generation of oncological treatments, including immunotherapy, to be more effective.

Citation: Marano G, Traversi G, Gaetani E, Gasbarrini A, Mazza M. Gut microbiota in women: The secret of psychological and physical well-being. *World J Gastroenterol* 2023; 29(45): 5945-5952

URL: <https://www.wjgnet.com/1007-9327/full/v29/i45/5945.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v29.i45.5945>

INTRODUCTION

Symbiotic microbes are present in several sites across the human body and contribute to the healthy physiology of our organism. The microbiota consists of all these microorganisms (bacteria, viruses, fungi and parasites) in a multicellular living organism that live in symbiosis with it without harming it. The assemblage of microbes and their respective genomes constitute our "microbiome" and contribute to shape and regulate many aspects of healthy bodily function. Gastrointestinal, skin, vaginal, and respiratory microbiomes are featured across those respective anatomical and functional sites[1].

In particular, the gastrointestinal tract is composed of different anatomical structures and is the theatre of complex biochemical processes, as well as parallel interactions with sensory, neurological, and endocrinological networks. Not surprisingly, the gut environment is characterized by a heterogeneous collection of distinct habitats along the rostral-caudal axis, which host the most abundant and diverse microbiota in the human body[2].

In recent years, a large body of studies on the human gut microbiota has increased impressively, deepening the awareness that the composition of the gut microbiota can greatly influence health status. Taking part in the digestive process, the gut microbiota plays a fundamental role in the synthesis of short-chain fatty acids, certain vitamins and essential amino acids, which contribute to the health of the body and the gut[3]. The gut microbiota has a strong influence on the immunoregulation, and on metabolic and cardiovascular health[4,5]. Furthermore, it can contribute to the correct functioning of the central nervous system and can even condition the response to drugs[3,6]. States of dysbiosis can adversely affect host health by promoting enrichment of pathogenic species, compromising the permeability of the intestinal barrier, and contributing to localized or generalized inflammatory states[7]. These conditions can lead to the onset of diseases such as cancer, inflammatory bowel disease, metabolic diseases, or even affect the health of other body districts *e.g.*, through gynaecological and dermatological diseases.

The gut microbiota is directly involved not only in the genesis of gastroenterological diseases, such as chronic inflammatory bowel disease, but also in the neurological and psychiatric fields due to the role of the so-called gut-brain axis[8]. The microbiota-gut-brain axis is a bidirectional communication system that connects the central nervous system with the gut microbiota. This axis describes a bidirectional interaction between the inside of the enteric environment (the intestinal epithelium, microbiota, enteric nervous system) and the outside (the central nervous system), connecting centers of the cognitive and emotional spheres, endocrine, and immunological activity. Growing scientific evidence indicates that the gut microbiota can modulate the functions of the central nervous system and *vice versa*[9]. The marked synergy and continuous exchange of information along this axis is possible because of the vast neurochemical pool available to the enteric nervous system, which innervates the gastrointestinal tract, comparable only to that of the central nervous system. Cells in both systems use the same chemical mediators[3]. Under stressful conditions, the autonomic nervous system can alter intestinal motility and blood flow, and lead to an excessive secretion of hormones and neurotransmitters such as adrenaline and cortisol[10]. All this translates into an alteration in the composition and functional activity of the gut microbiota (Figure 1).

Due to dysbiosis, injurious molecules released from the gut and mediators of the immune response (especially cytokines and interleukins) released during the subsequent chronic inflammatory process can damage and overcome the blood-brain barrier. As a result, brain areas that are critical for the control of emotions and behaviour, such as the limbic and frontal lobes, can be damaged[11]. The study conducted by Carloni *et al*[12] highlighted that alteration of the blood-brain barrier, induced by chronic intestinal inflammation, can be a cause of severe depressive and anxiety disorders.




Figure 1 Gut-brain axis interaction.

The emerging role of the gut microbiota in women

There is a complex controlled exchange of bacteria and other microorganisms from mother to child, even before birth. This dialogue prepares the newborn's immune system to face the outside world. Each individual acquires at birth his or her own personal gut microbiota, which will be an integral part of his or her defence mechanisms: An extremely heterogeneous set of bacteria, protozoa, fungi, and viruses that form the barrier between the external environment and the internal part of the organism (Figure 2). Its strength lies in diversity: A microbiota with high diversity can maintain certain functions and is usually a guarantee of a healthy immune system, while a low diversity microbiota can more easily undergo deficiencies and can cause impaired immune defences[13]. At birth, the digestive tract of newborns is completely sterile and is colonized immediately, starting from birth, by the microorganisms with which it comes into contact[13]. The gut microbiota of newborns delivered by caesarean section and/or those artificially breastfed appears profoundly different and takes longer to stabilize. In the first 4-36 mo of life, as a result of contact with parents, the external environment and food, the gut microbiota develops and changes rapidly.

In the first years of life, a real genetic "imprinting" of the gut microbiota takes place, which then determines the state of health in the rest of existence: There it is written whether or not there is predisposition toward certain diseases[14]. This is a crucial time in an individual's life, it occurs within the age of 4-6 years, and for this reason all factors that can alter it should be avoided[15].

At this age, any intervention on the bacterial flora takes on a very important meaning as it will leave an indelible mark on what will be the adult gut microbiota. From this individual basic nucleus, various changes continue to be observed at different stages of life or if particular pathological conditions are established.

Differences in gut microbiota between men and women

The factors that can influence the composition and balance of the gut microbiota in adulthood are the most diverse: Environmental conditions, stress levels, genetic predisposition, hormonal structure (such as pregnancy, menopause, premenstrual period), pharmacological therapies, eating habits, styles of life[16]. There are diversities between male and female gut microbiota[17] related to hormonal[18], autoimmune[19], ethnic[20] or purely physiological differences such as body mass index body mass index[21] and age[22]. Since microbes of the same species can produce different metabolites depending on the gender of the host and interact differently with sex hormones producing different effects [23] for better characterization it is important to take into account gender differences. These differences appear after puberty, suggesting that sexual hormones have a key role in influencing composition of gut microbiota[24]. The gut microbiota progressively develops along with the maturation of the immune and nervous system throughout the lifespan in men and women with resultant different microbial communities as well as immune and neuro-inflammatory pathways in adult males and females[24].

The embryo differentiates in a male direction due to the Y chromosome and the genes contained therein, which condition circulating testosterone levels. In mice, the microbiota also seems to follow the same paradigm. There is a basic female-type microbiota, which progressively differentiates into a male-type microbiota in parallel with the increase in circulating testosterone[25,26]. Boys and girls during childhood show significant differences in *Actinomycetota*, *Bacillota*, and *Bacteroidota* phyla amount with higher *Bacteroidota*/*Bacillota* ratio in boys compared to girls. In adult population men




Figure 2 Interplay between maternal and fetal microbiota.

and women maintain different amount of gut microbiota phyla (*Bacillota*, *Verrucomicrobia*, *Bacteroidota*, *Fusobacteria* and *Actinomycetota*)[27].

Gut microbiota during different stages of a woman's life

Puberty: In women, estrogens are important for differentiating the microbiota with health-promoting characteristics. The vaginal microbiota, whose population of microorganisms changes radically after puberty, is essential for the defence of the vagina throughout the fertile age, with a particular value for the pregnancy protection. After menopause, the impoverishment of the microbiota by sexual hormones deficiency leads to a depletion of many of its local, loco-regional and systemic beneficial health functions[24-26].

The estrobolome is capable of producing and metabolizing estrogen, which plays a key physiological role in maintaining women's health therefore modulating estrogen levels can have effects on weight, libido, and even mood, important dimensions for well-being of every person[28]. As regards estrogens in particular, intestinal microorganisms can modify their levels mainly through the activity of certain enzymes with which some bacteria are equipped, thus transforming estrogens into their active form capable of triggering physiological effects. An altered gut microbiota may play a leading role in the onset and development of reproductive system disorders with hormonal imbalances, such as polycystic ovary syndrome, endometriosis, and infertility[29]. Similarly, it has been suggested that microbiota imbalances with impairment of the gut's physiological "barrier" function and consequent translocation of microbes and/or microbial components have an active role in the development of vaginal and urinary tract infections[30,31].

Pregnancy: Pregnancy represents the period most clearly exemplifying the existing relationships between microbiota and hormone levels, where the modification of gut bacteria produces relevant and evident alterations ranging from a "low-grade" inflammatory condition typical of the pregnant state, to a reduced glucose tolerance, increased adiposity, among other transmissible as has been demonstrated in some experimental observations conducted on laboratory mice transplanted with the microbiota of women in the third trimester of pregnancy[30,31]. During pregnancy, the gut microbiota primarily defends the health of the mother, for example, by helping her not to develop gestational diabetes, and at the same time, it also preserves that of the child who will be exposed to the first "transfer" of microorganisms at the time of birth[32]. The vertical transmission of the microbiota from mother to fetus, which appears to begin during intrauterine life, contributes to the development of the child's gastrointestinal microbiota[33]. Going toward the third trimester, the relative abundance of some bacteria that are then transferred to the newborn in the peripartum (in the case of vaginal birth) increases: In fact, the child's gut microbiota consists of 22% bacteria derived from the mother's gut microbiota, particularly *Bifidobacteria*, *Bacteroides*, and *Escherichia coli*[31]. A more recent study showed important differences in the gut microbiota related to the sex of the individual and allowed the identification of microorganisms that remain in the female gut until fertile age and are then transmitted from mother to child during birth[34]. These strains are part of the genus *Bifidobacterium*, a group of microorganisms that has been much studied because they are associated with a positive impact on host health. Thus, knowing the composition of the microbiota during pregnancy can be a most useful tool both for preserving a woman's health status and for "working" to ensure that a healthy stock of microorganisms is inherited at the time of birth.

Menopause: In menopausal women it has been observed a depletion of *Bacillota* and a progressive reorganization of the gut microbiome (post-menopausal women tend to be more similar to age-matched men as to pre-menopausal women regarding *e.g.*, *Bacillota* to *Bacteroidota* ratio). This could suggest that testosterone may play a major role in shaping the gut microbiota, but more studies focusing on different ages with data comparing both male and female subjects are warranted in order to enlighten the distinct role of sexual hormones as direct or indirect choirmasters of human gut microbiota[27].

Gut microbiota and diseases in women

The fact that the gut microbiota differs between males and females can cause some sex-specific changes in immunity and it has been demonstrated that differences in male and female microbiota can drive chronic diseases, ranging from gastrointestinal inflammatory and metabolic conditions to neurological, cardiovascular, and respiratory illnesses[35]. Gut microbiota has a bidirectional relationship with inflammation and depending on its composition, it can inhibit or stimulate inflammatory pathways. Altered gut microbiota can contribute to subacute systemic inflammation reinforcing the disease state[36].

Potential role of the gut microbiota and its dysbiosis has been described in many diseases affecting women, such as polycystic ovarian syndrome, female cancers (breast, cervical, and ovarian cancer) and postmenopausal period illnesses such as menopausal obesity, Alzheimer's disease, and bone diseases[37]. The International Cancer Microbiome Consortium has suggested a key role of the gut microbiota in disease development, tumour protection, response to therapies, and control of side effects of cancer treatments[38]. Wang *et al*[39] found that the feces composition of women with benign pathology differed from that of women suffering from ovarian carcinoma where *Akkermansia* were low. The researchers showed that transferring gut microbes from ovarian carcinoma patients to mice with the same tumour increased their growth. Subsequent addition of *Akkermansia* bacteria to the microbiota transplant slowed tumour growth, probably due to increased T-cell activation. *Akkermansia* supplementation increased levels of short-chain fatty acids, which are associated with an improved ability of specific T lymphocytes to kill tumour cells.

The profile of the gut microbiota and its metabolites can serve as biomarkers for breast cancer. Some potentially pathogenic bacteria such as *Clostridium*, *Citrobacter*, and *Escherichia* may negatively influence the development and progression of breast cancer cells[40,41]. However, some bacterial species have shown a protective effect against this disease. *Faecalibacterium prausnitzii* and *Roseburia intestinalis* are producers of butyrate, this molecule has powerful anti-inflammatory and intestinal permeability-reducing activities, demonstrating a protective effect against the development of tumour cells[42,43].

The gut appears to be directly connected to the breast through an "axis", which may underlie a correlation between gut and breast microbiota dysfunction: The gut microbiota-mammary axis[44]. Altered composition of the various bacterial populations, no longer harmoniously represented within the microbiota, could affect not only local intestinal inflammation, but also systemic inflammation through "hyperactivation" of the immune system. In fact, several studies have shown the presence of dysbiosis in the breast microbiota of women with cancer, but not of healthy women[45]. Costantini *et al*[46] pointed out that the microbiota may predispose to neoplastic transformation. The clinical importance of this observation suggests that "working" on the microbiota to promote its rebalancing could result in a subsequent reduction in the risk of tumour transformation (Table 1).

The gut microbiota also actively and importantly influences the effectiveness of the response to immunotherapy. Several studies have observed that patients in whom immunotherapy is effective have a gut microbiome very rich in different species, whereas in patients who are resistant to this treatment the microbiota repertoire is more limited. Thus, the gut microbiota represents a first important modulation tool in regulating the anti-tumour immune response[47]. For example, *Bacteroidota* are biomarkers of response in melanoma patients: Their presence is associated with a possible reduction in response rates. In melanoma patients, the presence of three types of bacteria (*Bifidobacterium pseudocatenulatum*, *Roseburia* spp. and *Akkermansia muciniphila*) appears to be associated with better response to immunotherapy, but the link between microbiota and response to therapy involves different species in different patient groups [48]. On the other hand, *Faecalibacterium*, *Bifidobacterium* and *Oscillospiraceae* can improve the response to immune checkpoint inhibitors[49]. In addition, the gut microbiota may also play a role in the response to chemotherapy and in reducing the impact of treatment side effects, such as oral mucositis and inflammation[50,51].

CONCLUSION

Although there is a growing interest on influence of the gut microbiota on other organs, our knowledge on the role of gut microbiota in diseases is currently still limited. Some researchers have focused on the variation of the gut microbiome *via* diet and through supplementation with pre/pro/postbiotics in various female health issues. Interdisciplinary studies on the microbiota are achieving progress toward a better understanding of the molecular basis responsible for microorganism-host interaction and possible positive or negative implications on women's health. The modulation of the gut microbiome as a both preventative and therapeutic strategy needs to be accomplished. Theoretically, enriching the gut microbiota with "good" bacteria at the expense of "bad" bacteria, good health is promoted. However, there cannot be an ideal microbiota that is the same for everyone: Genes and individual characteristics play a determining role. Increasingly advanced techniques for analyzing the gut microbiota and its functions may also contribute to the development of precision medicine.

Table 1 Summary of gut microbiota in women

	Summary of gut microbiota
Healthy female[27]	Decreased: <i>Bacteroides</i> abundance with ↑diversity than in men Increased: <i>Lactobacillus</i> , <i>Bifidobacterium</i> and <i>Parabacteroides</i> than in men
Menstruation[29]	Decreased: <i>Bacteroidota</i> , <i>Butyrivibrio</i> , <i>Extibacter</i> , <i>Megasphaera</i> , <i>Parabacteroides</i>
Pregnancy[31-33]	Increased: <i>Actionbacteria</i> , <i>Proteobacteria</i> , <i>Akkermansia</i> , <i>Bifidobacterium</i> , <i>Bacillota</i> Decreased: Short chain fatty acids producers
Polycystic ovarian syndrome[36]	Increased: <i>Phocaeicola vulgatus</i> , <i>Bacillota</i> , <i>Streptococcus</i> , <i>Escherichia/Shigella</i> Decreased: <i>Tenericutes</i> , <i>Akkermansia</i> , <i>Oscillospiraceae</i>
Menopause[22]	Increased: <i>Bacillota</i> , <i>Roseburia</i> , <i>Lachnospira</i> , <i>Bacteroidota</i> Decreased: <i>Bilophila</i> , <i>Prevotella</i> , <i>Parabacteroides</i>
Breast cancer[40,41]	Increased: <i>Eubacteriales</i> , <i>Bacillus</i> , <i>Enterobacteriaceae</i> , <i>Staphylococcus</i>
Cervical cancer[37]	Increased: <i>Proteobacteria</i> , <i>Prevotella</i> , <i>Porphyromonas</i> , <i>Dialister</i> Decreased: <i>Bacteroides</i> , <i>Alistipes</i> , <i>Lachnospiraceae</i>
Ovarian cancer[39]	Increased: <i>Prevotella</i> , <i>Coriobacteriaceae</i> , <i>Bifidobacterium</i>

FOOTNOTES

Author contributions: Marano G and Mazza M designed the research study and wrote the manuscript; Traversi G performed the research; Gaetani E and Gasbarrini A supervised and made substantial contributions to the conception of the work; and all authors have read and approve the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Giuseppe Marano 0000-0001-7058-4927; Antonio Gasbarrini 0000-0003-4863-6924; Marianna Mazza 0000-0002-3007-8162.

S-Editor: Wang JJ

L-Editor: A

P-Editor: Cai YX

REFERENCES

- Kennedy MS, Chang EB. The microbiome: Composition and locations. *Prog Mol Biol Transl Sci* 2020; **176**: 1-42 [PMID: 33814111 DOI: 10.1016/bs.pmbts.2020.08.013]
- Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* 2012; **486**: 207-214 [PMID: 22699609 DOI: 10.1038/nature11234]
- Marano G, Mazza M, Lisci FM, Ciliberto M, Traversi G, Kotzalis GD, De Berardis D, Laterza L, Sani G, Gasbarrini A, Gaetani E. The Microbiota-Gut-Brain Axis: Psychoneuroimmunological Insights. *Nutrients* 2023; **15** [PMID: 36986226 DOI: 10.3390/nu15061496]
- Garg S, Sharma N, Bharmjeet, Das A. Unraveling the intricate relationship: Influence of microbiome on the host immune system in carcinogenesis. *Cancer Rep (Hoboken)* 2023; e1892 [PMID: 37706437 DOI: 10.1002/cnr2.1892]
- Hamjane N, Mechita MB, Nourouti NG, Barakat A. Gut microbiota dysbiosis -associated obesity and its involvement in cardiovascular diseases and type 2 diabetes. A systematic review. *Microvasc Res* 2023; **151**: 104601 [PMID: 37690507 DOI: 10.1016/j.mvr.2023.104601]
- Khan I. Drugs and gut microbiome interactions-an emerging field of tailored medicine. *BMC Pharmacol Toxicol* 2023; **24**: 43 [PMID: 37649091 DOI: 10.1186/s40360-023-00684-9]
- Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, Gionchetti P, Schrezenmeier J, Foelsch UR, Schreiber S, Campieri M. Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. *World J Gastroenterol* 2006; **12**: 5978-5986 [PMID: 17009396 DOI: 10.3748/wjg.v12.i37.5978]
- Zhou Y, Chen Y, He H, Peng M, Zeng M, Sun H. The role of the indoles in microbiota-gut-brain axis and potential therapeutic targets: A focus on human neurological and neuropsychiatric diseases. *Neuropharmacology* 2023; **239**: 109690 [PMID: 37619773 DOI: 10.1016/j.neuropharm.2023.109690]

- 9 **Grenham S**, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. *Front Physiol* 2011; **2**: 94 [PMID: 22162969 DOI: 10.3389/fphys.2011.00094]
- 10 **Foster JA**, Rinaman L, Cryan JF. Stress & the gut-brain axis: Regulation by the microbiome. *Neurobiol Stress* 2017; **7**: 124-136 [PMID: 29276734 DOI: 10.1016/j.ynstr.2017.03.001]
- 11 **Generoso JS**, Giridharan VV, Lee J, Macedo D, Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. *Braz J Psychiatry* 2021; **43**: 293-305 [PMID: 32667590 DOI: 10.1590/1516-4446-2020-0987]
- 12 **Carlioni S**, Bertocchi A, Mancinelli S, Bellini M, Erreni M, Borreca A, Braga D, Giugliano S, Mozzarelli AM, Manganaro D, Fernandez Perez D, Colombo F, Di Sabatino A, Pasini D, Penna G, Matteoli M, Lodato S, Rescigno M. Identification of a choroid plexus vascular barrier closing during intestinal inflammation. *Science* 2021; **374**: 439-448 [PMID: 34672740 DOI: 10.1126/science.abc6108]
- 13 **Pantazi AC**, Balasa AL, Mihai CM, Chisnoiu T, Lupu VV, Kassim MAK, Mihai L, Precus CE, Chirila SI, Lupu A, Andrusca A, Ionescu C, Cuzic V, Cambrea SC. Development of Gut Microbiota in the First 1000 Days after Birth and Potential Interventions. *Nutrients* 2023; **15** [PMID: 37630837 DOI: 10.3390/nu15163647]
- 14 **Henrick BM**, Rodriguez L, Lakshmikanth T, Pou C, Henckel E, Arzoomand A, Olin A, Wang J, Mikes J, Tan Z, Chen Y, Ehrlich AM, Bernhardtson AK, Mugabo CH, Ambrosiani Y, Gustafsson A, Chew S, Brown HK, Prambs J, Bohlin K, Mitchell RD, Underwood MA, Smilowitz JT, German JB, Frese SA, Brodin P. Bifidobacteria-mediated immune system imprinting early in life. *Cell* 2021; **184**: 3884-3898.e11 [PMID: 34143954 DOI: 10.1016/j.cell.2021.05.030]
- 15 **Xiao L**, Zhao F. Microbial transmission, colonisation and succession: from pregnancy to infancy. *Gut* 2023; **72**: 772-786 [PMID: 36720630 DOI: 10.1136/gutjnl-2022-328970]
- 16 **Ma L**, Yan Y, Webb RJ, Li Y, Mehrabani S, Xin B, Sun X, Wang Y, Mazidi M. Psychological Stress and Gut Microbiota Composition: A Systematic Review of Human Studies. *Neuropsychobiology* 2023; **82**: 247-262 [PMID: 37673059 DOI: 10.1159/000533131]
- 17 **Kim YS**, Unno T, Kim BY, Park MS. Sex Differences in Gut Microbiota. *World J Mens Health* 2020; **38**: 48-60 [PMID: 30929328 DOI: 10.5534/wjmh.190009]
- 18 **Fukui H**, Xu X, Miwa H. Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. *J Neurogastroenterol Motil* 2018; **24**: 367-386 [PMID: 29969855 DOI: 10.5056/jnm18071]
- 19 **Yurkovetskiy L**, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, Antonopoulos D, Umesaki Y, Chervonsky AV. Gender bias in autoimmunity is influenced by microbiota. *Immunity* 2013; **39**: 400-412 [PMID: 23973225 DOI: 10.1016/j.immuni.2013.08.013]
- 20 **Mueller S**, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, Cresci A, Silvi S, Orpianesi C, Verdenelli MC, Clavel T, Koebnick C, Zunft HJ, Doré J, Blaut M. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. *Appl Environ Microbiol* 2006; **72**: 1027-1033 [PMID: 16461645 DOI: 10.1128/AEM.72.2.1027-1033.2006]
- 21 **Gao X**, Zhang M, Xue J, Huang J, Zhuang R, Zhou X, Zhang H, Fu Q, Hao Y. Body Mass Index Differences in the Gut Microbiota Are Gender Specific. *Front Microbiol* 2018; **9**: 1250 [PMID: 29988340 DOI: 10.3389/fmicb.2018.01250]
- 22 **Salles N**. Basic mechanisms of the aging gastrointestinal tract. *Dig Dis* 2007; **25**: 112-117 [PMID: 17468545 DOI: 10.1159/000099474]
- 23 **Jahng J**, Kim YS. Why Should We Contemplate on Gender Difference in Functional Gastrointestinal Disorders? *J Neurogastroenterol Motil* 2017; **23**: 1-2 [PMID: 28049860 DOI: 10.5056/jnm16209]
- 24 **Yoon K**, Kim N. Roles of Sex Hormones and Gender in the Gut Microbiota. *J Neurogastroenterol Motil* 2021; **27**: 314-325 [PMID: 33762473 DOI: 10.5056/jnm20208]
- 25 **Baker JM**, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. *Maturitas* 2017; **103**: 45-53 [PMID: 28778332 DOI: 10.1016/j.maturitas.2017.06.025]
- 26 **Hokanson KC**, Hernández C, Deitzler GE, Gaston JE, David MM. Sex shapes gut-microbiota-brain communication and disease. *Trends Microbiol* 2023 [PMID: 37813734 DOI: 10.1016/j.tim.2023.08.013]
- 27 **Valeri F**, Endres K. How biological sex of the host shapes its gut microbiota. *Front Neuroendocrinol* 2021; **61**: 100912 [PMID: 33713673 DOI: 10.1016/j.yfrne.2021.100912]
- 28 **Marano G**, Traversi G, Mazza M. Web-mediated Counseling Relationship in Support of the New Sexuality and Affectivity During the COVID-19 Epidemic: A Continuum Between Desire and Fear. *Arch Sex Behav* 2021; **50**: 753-755 [PMID: 33479805 DOI: 10.1007/s10508-020-01908-3]
- 29 **Bednarska-Czerwińska A**, Morawiec E, Zmarzły N, Szapski M, Jendrysek J, Pecyna A, Zapletal-Pudelko K, Malysiak W, Sirek T, Ossowski P, Łach A, Boroń D, Bogdał P, Bernet A, Grabarek BO. Dynamics of Microbiome Changes in the Endometrium and Uterine Cervix during Embryo Implantation: A Comparative Analysis. *Med Sci Monit* 2023; **29**: e941289 [PMID: 37543728 DOI: 10.12659/MSM.941289]
- 30 **Piancone E**, Fosso B, Marzano M, De Robertis M, Notario E, Oranger A, Manzari C, Bruno S, Visci G, Defazio G, D'Erchia AM, Filomena E, Maio D, Minelli M, Vergallo I, Pesole G. Natural and after colon washing fecal samples: the two sides of the coin for investigating the human gut microbiome. *Sci Rep* 2022; **12**: 17909 [PMID: 36284112 DOI: 10.1038/s41598-022-20888-z]
- 31 **Inversetti A**, Zambella E, Guarano A, Dell'Avanzo M, Di Simone N. Endometrial Microbiota and Immune Tolerance in Pregnancy. *Int J Mol Sci* 2023; **24** [PMID: 36769318 DOI: 10.3390/ijms24032995]
- 32 **Ferretti P**, Pasolli E, Tett A, Asnicar F, Gorfer V, Fedi S, Armanini F, Truong DT, Manara S, Zolfo M, Beghini F, Bertorelli R, De Sanctis V, Bariletti I, Canto R, Clementi R, Cologna M, Crifò T, Cusumano G, Gottardi S, Innamorati C, Masè C, Postai D, Savoi D, Duranti S, Lugli GA, Mancabelli L, Turrone F, Ferrario C, Milani C, Mangifesta M, Anzalone R, Viappiani A, Yassour M, Vlamakis H, Xavier R, Collado CM, Koren O, Tateo S, Soffiati M, Pedrotti A, Ventura M, Huttenhower C, Bork P, Segata N. Mother-to-Infant Microbial Transmission from Different Body Sites Shapes the Developing Infant Gut Microbiome. *Cell Host Microbe* 2018; **24**: 133-145.e5 [PMID: 30001516 DOI: 10.1016/j.chom.2018.06.005]
- 33 **Tirone C**, Paladini A, De Maio F, Tersigni C, D'Ippolito S, Di Simone N, Monzo FR, Santarelli G, Bianco DM, Tana M, Lio A, Menzella N, Posteraro B, Sanguinetti M, Lanzone A, Scambia G, Vento G. The Relationship Between Maternal and Neonatal Microbiota in Spontaneous Preterm Birth: A Pilot Study. *Front Pediatr* 2022; **10**: 909962 [PMID: 35935374 DOI: 10.3389/fped.2022.909962]
- 34 **Tarracchini C**, Alessandri G, Fontana F, Rizzo SM, Lugli GA, Bianchi MG, Mancabelli L, Longhi G, Argentini C, Vergna LM, Anzalone R, Viappiani A, Turrone F, Taurino G, Chiu M, Arboleya S, Gueimonde M, Bussolati O, van Sinderen D, Milani C, Ventura M. Genetic strategies for sex-biased persistence of gut microbes across human life. *Nat Commun* 2023; **14**: 4220 [PMID: 37452041 DOI: 10.1038/s41467-023-39931-2]
- 35 **Cox LM**, Abou-El-Hassan H, Maghzi AH, Vincentini J, Weiner HL. The sex-specific interaction of the microbiome in neurodegenerative diseases. *Brain Res* 2019; **1724**: 146385 [PMID: 31419428 DOI: 10.1016/j.brainres.2019.146385]

- 36 **Al Bander Z**, Nitert MD, Mousa A, Naderpoor N. The Gut Microbiota and Inflammation: An Overview. *Int J Environ Res Public Health* 2020; **17** [PMID: 33086688 DOI: 10.3390/ijerph17207618]
- 37 **Siddiqui R**, Makhoulf Z, Alharbi AM, Alfahemi H, Khan NA. The Gut Microbiome and Female Health. *Biology (Basel)* 2022; **11** [PMID: 36421397 DOI: 10.3390/biology11111683]
- 38 **Scott AJ**, Alexander JL, Merrifield CA, Cunningham D, Jobin C, Brown R, Alverdy J, O'Keefe SJ, Gaskins HR, Teare J, Yu J, Hughes DJ, Verstraeten H, Burton J, O'Toole PW, Rosenberg DW, Marchesi JR, Kinross JM. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. *Gut* 2019; **68**: 1624-1632 [PMID: 31092590 DOI: 10.1136/gutjnl-2019-318556]
- 39 **Wang Z**, Qin X, Hu D, Huang J, Guo E, Xiao R, Li W, Sun C, Chen G. Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer. *Cell Rep* 2022; **41**: 111890 [PMID: 36577369 DOI: 10.1016/j.celrep.2022.111890]
- 40 **Yang P**, Wang Z, Peng Q, Lian W, Chen D. Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study. *Evol Bioinform Online* 2021; **17**: 11769343211057573 [PMID: 34795472 DOI: 10.1177/11769343211057573]
- 41 **Sohail S**, Burns MB. Integrating current analyses of the breast cancer microbiome. *PLoS One* 2023; **18**: e0291320 [PMID: 37699008 DOI: 10.1371/journal.pone.0291320]
- 42 **Bobin-Dubigeon C**, Bard JM, Luu TH, Le Vacon F, Nazih H. Basolateral Secretion from Caco-2 Cells Pretreated with Fecal Waters from Breast Cancer Patients Affects MCF7 Cell Viability. *Nutrients* 2020; **13** [PMID: 33374116 DOI: 10.3390/nu13010031]
- 43 **Shrode RL**, Knobbe JE, Cady N, Yadav M, Hoang J, Cherwin C, Curry M, Garje R, Vikas P, Sugg S, Phadke S, Filardo E, Mangalam AK. Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria. *Sci Rep* 2023; **13**: 526 [PMID: 36631533 DOI: 10.1038/s41598-023-27436-3]
- 44 **Zhang S**, Zhang W, Ren H, Xue R, Wang Z, Lv Q. Mendelian randomization analysis revealed a gut microbiota-mammary axis in breast cancer. *Front Microbiol* 2023; **14**: 1193725 [PMID: 37680534 DOI: 10.3389/fmicb.2023.1193725]
- 45 **Filippone A**, Rossi C, Rossi MM, Di Micco A, Maggiore C, Forcina L, Natale M, Costantini L, Merendino N, Di Leone A, Franceschini G, Masetti R, Magno S. Endocrine Disruptors in Food, Estrobolome and Breast Cancer. *J Clin Med* 2023; **12** [PMID: 37176599 DOI: 10.3390/jcm12093158]
- 46 **Costantini L**, Magno S, Albanese D, Donati C, Molinari R, Filippone A, Masetti R, Merendino N. Characterization of human breast tissue microbiota from core needle biopsies through the analysis of multi hypervariable 16S-rRNA gene regions. *Sci Rep* 2018; **8**: 16893 [PMID: 30442969 DOI: 10.1038/s41598-018-35329-z]
- 47 **Pasanisi P**, Gariboldi M, Verderio P, Signoroni S, Mancini A, Rivoltini L, Milione M, Masci E, Ciniselli CM, Bruno E, Macciotta A, Belfiore A, Ricci MT, Gargano G, Morelli D, Apolone G, Vitellaro M. A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. *Integr Cancer Ther* 2019; **18**: 1534735419846400 [PMID: 31055940 DOI: 10.1177/1534735419846400]
- 48 **Lee KA**, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Míguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. *Nat Med* 2022; **28**: 535-544 [PMID: 35228751 DOI: 10.1038/s41591-022-01695-5]
- 49 **Halsey TM**, Thomas AS, Hayase T, Ma W, Abu-Sbeih H, Sun B, Parra ER, Jiang ZD, DuPont HL, Sanchez C, El-Himri R, Brown A, Flores I, McDaniel L, Ortega Turrubiates M, Hensel M, Pham D, Watowich SS, Hayase E, Chang CC, Jenq RR, Wang Y. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. *Sci Transl Med* 2023; **15**: eabq4006 [PMID: 37315113 DOI: 10.1126/scitranslmed.abq4006]
- 50 **Bruno JS**, Al-Qadami GH, Laheij AMGA, Bossi P, Fregnani ER, Wardill HR. From Pathogenesis to Intervention: The Importance of the Microbiome in Oral Mucositis. *Int J Mol Sci* 2023; **24** [PMID: 37175980 DOI: 10.3390/ijms24098274]
- 51 **Mondal P**, Meeran SM. The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance. *Cancer Metastasis Rev* 2023; **2023** [PMID: 37707749 DOI: 10.1007/s10555-023-10138-7]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

